Oculis Holding AG OCS
7.46 USD -0.05 (-0.73%)
As ofNov 18, 2026, 10:45 AM EST
7.39 Day range 7.75
6.78 52-week range 34.48
- YTD
- -62.67%
- 1 year
- -61.35%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
benzinga.com Oculis Wins FDA IND Clearance For Privosegtor In Acute MS Relapses, Including Optic Neuritis And Ambulatory Relapses, With Primary Endpoint As Early As Three Months FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program…
globenewswire.com Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program…
globenewswire.com Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
zacks.com Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 384.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…benzinga.com Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $40 Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $45 to $40.
benzinga.com Oculis Holding Q3 EPS $(0.37) Beats $(0.49) Estimate, Sales $8.619K Miss $290.000K Estimate Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 5.13 percent increase over losses of…
benzinga.com HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
benzinga.com Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective,…
benzinga.com Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trialsPrecision Medicine Approach…
